Zum Hauptinhalt wechseln

Leider unterstützen wir Ihren Browser nicht vollständig. Wenn Sie die Möglichkeit dazu haben, nehmen Sie bitte ein Upgrade auf eine neuere Version vor oder verwenden Sie Mozilla Firefox, Microsoft Edge, Google Chrome oder Safari 14 bzw. eine neuere Version. Wenn Sie nicht dazu in der Lage sind und Unterstützung benötigen, senden Sie uns bitte Ihr Feedback.

Wir würden uns über Ihr Feedback zu diesen neuen Seiten freuen.Sagen Sie uns, was Sie denken Wird in neuem Tab/Fenster geöffnet

Elsevier
Bei Elsevier publizieren
Video

ClinicalKey AI in action: Can I use an SGLT2 agent for management of HFpEF in a non-diabetic patient

| 2 Min. zur Lektüre

ClinicalKey AI combines trusted, evidence-based clinical content with conversational search powered by generative AI to support clinicians in delivering high-quality patient care.  Clinicians gain a powerful ally with ClinicalKey AI by providing quick access to trusted clinical knowledge and allowing them to focus on what truly matters, quality patient care. Interested healthcare organizations can contact us Wird in neuem Tab/Fenster geöffnet today to learn more.  

SGLT

Yes, you can use a sodium-glucose co-transporter-2 (SGLT2) inhibitor such as empagliflozin or dapagliflozin for the management of heart failure with preserved ejection fraction (HFpEF) in a non-diabetic patient. SGLT2 inhibitors like empagliflozin and dapagliflozin have been shown to reduce the risk of hospitalization for heart failure and improve symptoms and health-related quality of life in patients with HFpEF, regardless of their diabetes status.[1-3] The EMPEROR-Preserved trial demonstrated improved outcomes (21% reduction in cardiovascular death or HF hospitalization) in patients with HFpEF treated with empagliflozin, with benefits established in both diabetic and non-diabetic patients.[2][4] The DELIVER trial, which tested dapagliflozin, is expected to report its results soon, and it is anticipated that it may provide further evidence supporting the use of SGLT2 inhibitors in HFpEF.[3] The FDA has approved the use of empagliflozin for reducing the risk of cardiovascular death and HF hospitalization in patients with HFpEF.[2][5] Sotagliflozin, an SGLT1/2 inhibitor, has also been shown to reduce heart failure hospitalization in patients with HFpEF.[3][6]

  1. Heart Failure Wird in neuem Tab/Fenster geöffnet. McMurray, John J.V., Pfeffer, Marc A. In Goldman-Cecil Medicine (pp. 262).

  2. Chronic Heart Failure With Preserved Ejection Fraction, Management.  Wird in neuem Tab/Fenster geöffnet Elsevier ClinicalKey Clinical Overview

  3. Heart Failure with Preserved and Mildly Reduced Ejection Fraction.  Wird in neuem Tab/Fenster geöffnet Lam,, Carolyn S.P., Shah,, Sanjiv J., Solomon, Scott D. In Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine (pp. 1007).

  4. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. Wird in neuem Tab/Fenster geöffnet Anker SD, Butler J, Filippatos G, et al. The New England Journal of Medicine. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038.

  5. JARDIANCE. Label via DailyMed Wird in neuem Tab/Fenster geöffnet. Food and Drug Administration (DailyMed) FDA

  6. INPEFA. Label via DailyMed Wird in neuem Tab/Fenster geöffnet. Food and Drug Administration (DailyMed) FDA Answer generated on March 31, 2024 Note: User acknowledges that these materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.